Eli Lilly’s revenue growth is mainly due to its weight-loss and obesity franchise, blockbuster drugs like Mounjaro, Zepbound, and new developments such as the oral GLP-1 drug Foundayo and the pipeline drug Retatrutide, which drives significant investor focus.